Lifastuzumab vedotin

Drug Profile

Lifastuzumab vedotin

Alternative Names: Anti-NaPi2b; DNIB-0600A; NaPi2b-ADC; NaPi3b; RG-7599; RO-5541081

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Type IIb sodium-phosphate cotransporter protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 May 2016 Genentech completes a phase-I clinical trial in Ovarian cancer and Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA and Spain (IV) (NCT01363947)
  • 31 May 2014 Efficacy data from a phase I trial in Ovarian cancer or Non-small cell lung cancer presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top